Reviewing Genenta Science (NASDAQ:GNTA) & Kalaris Therapeutics (NASDAQ:KLRS)

Genenta Science (NASDAQ:GNTA) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

Earnings & Valuation

This table compares Genenta Science and Kalaris Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genenta Science	N/A	N/A	-$7.39 million	N/A	N/A
Kalaris Therapeutics	N/A	N/A	-$43.44 million	($2.15)	-2.20

Insider & Institutional Ownership

15.1% of Genenta Science shares are owned by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are owned by institutional investors. 29.0% of Genenta Science shares are owned by insiders. Comparatively, 68.1% of Kalaris Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Genenta Science and Kalaris Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genenta Science	1	0	0	0	1.00
Kalaris Therapeutics	1	1	6	1	2.78

Kalaris Therapeutics has a consensus price target of $15.60, indicating a potential upside of 230.51%. Given Kalaris Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Kalaris Therapeutics is more favorable than Genenta Science.

Profitability

This table compares Genenta Science and Kalaris Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Genenta Science	N/A	N/A	N/A
Kalaris Therapeutics	N/A	-72.78%	-43.49%

Risk & Volatility

Genenta Science has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500. Comparatively, Kalaris Therapeutics has a beta of 0.15, meaning that its stock price is 85% less volatile than the S&P 500.

Summary

Kalaris Therapeutics beats Genenta Science on 6 of the 10 factors compared between the two stocks.

About Genenta Science

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.

About Kalaris Therapeutics

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.